On January 12, the Xuchang Police in Henan Province published a short announcement. The police claimed that manager Zhang of the KingMed Diagnostics’ office in Zhengzhou City, Henan Province, “violated the provisions of the Prevention and Control of Infectious Diseases Act and committed acts that caused the spread of the (COVID-19) virus or which had a serious risk of causing such a spread.” The police started an investigation into the case.
In early January, Xuchang found COVID cases in its affiliated city Yuzhou and locked down Yuzhou. Last month, it became the second city in the province to be locked down after Xi’an.
KingMed Diagnostics is the largest medical lab testing COVID-19 in China. By November 2011, it had completed 220 million COVID tests, which was the highest number among all labs in the world. Zhong Nanshan, a communist regime endorsed COVID-19 expert doctor, who speaks for the government from time to time, created the company.
Since the police didn’t disclose what Zhang did, there were rumors on the Internet about what happened. One guess was that KingMed spread the virus and in the meantime collected money from the government for testing it. Another guess was that KingMed received many testing samples but couldn’t complete them in the required time-frame; then the manager reported the test results were ALL negative and discarded the samples that they didn’t have time to test. However, later the government found there were positives cases.
The next day, January 13, KingMed published a statement that the Zhengzhou KingMed office received the Xuchang City’s request to participate in the COVID testing. Zhang and five other people formed a supporting team and came to Yuzhou. They worked on the testing from January 2 to 9. The company’s statement also denied the rumors of “actively spreading the virus,” “faking test results,” and “hiding infection numbers.” The company said that it reserves the right to go after those who spread rumors.
1. BBC, January 13, 2022
2. China News Agency Finance, January 13, 2022